Veterinary Medicines

Heptavac P plus

Authorised
  • Clostridium chauvoei, toxoid
  • Clostridium chauvoei, strain 1048, cells and equivalent toxoid
  • Clostridium chauvoei, strain 658, cells and equivalent toxoid
  • Clostridium chauvoei, strain 657, cells and equivalent toxoid
  • Clostridium chauvoei, strain 656, cells and equivalent toxoid
  • Clostridium chauvoei, strain 655, cells and equivalent toxoid
  • Tetanus toxoid adsorbed
  • Clostridium septicum, toxoid
  • Clostridium perfringens, type C, strain 578, beta toxoid
  • Clostridium perfringens, type C, strain 554, beta toxoid
  • Clostridium novyi, toxoid
  • Bibersteinia trehalosi, serotype T15, strain S1105/84, Inactivated
  • Bibersteinia trehalosi, serotype T10, strain S1075/81, Inactivated
  • Bibersteinia trehalosi, serotype T4, strain S1085/81, Inactivated
  • Bibersteinia trehalosi, serotype T3, strain S1109/84, Inactivated
  • Mannheimia haemolytica, serotype A9, strain S994/77, Inactivated
  • Mannheimia haemolytica, serotype A7, strain S1078/81, Inactivated
  • Mannheimia haemolytica, serotype A6, strain S1084/81, Inactivated
  • Mannheimia haemolytica, serotype A2, strain S1126/92, Inactivated
  • Mannheimia haemolytica, serotype A1, strain S1006/77, Inactivated
  • Immunoglobulins against Clostridium perfringens epsilon toxoid, Equine
Download as PDF

Product identification

Medicine name:
Heptavac P plus
Active substance:
  • Clostridium chauvoei, toxoid
  • Clostridium chauvoei, strain 1048, cells and equivalent toxoid
  • Clostridium chauvoei, strain 658, cells and equivalent toxoid
  • Clostridium chauvoei, strain 657, cells and equivalent toxoid
  • Clostridium chauvoei, strain 656, cells and equivalent toxoid
  • Clostridium chauvoei, strain 655, cells and equivalent toxoid
  • Tetanus toxoid adsorbed
  • Clostridium septicum, toxoid
  • Clostridium perfringens, type C, strain 578, beta toxoid
  • Clostridium perfringens, type C, strain 554, beta toxoid
  • Clostridium novyi, toxoid
  • Bibersteinia trehalosi, serotype T15, strain S1105/84, Inactivated
  • Bibersteinia trehalosi, serotype T10, strain S1075/81, Inactivated
  • Bibersteinia trehalosi, serotype T4, strain S1085/81, Inactivated
  • Bibersteinia trehalosi, serotype T3, strain S1109/84, Inactivated
  • Mannheimia haemolytica, serotype A9, strain S994/77, Inactivated
  • Mannheimia haemolytica, serotype A7, strain S1078/81, Inactivated
  • Mannheimia haemolytica, serotype A6, strain S1084/81, Inactivated
  • Mannheimia haemolytica, serotype A2, strain S1126/92, Inactivated
  • Mannheimia haemolytica, serotype A1, strain S1006/77, Inactivated
  • Immunoglobulins against Clostridium perfringens epsilon toxoid, Equine
Target species:
  • Sheep
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Clostridium chauvoei, toxoid
    1.00
    90% protective dose in guinea pig
    /
    2.00
    millilitre(s)
  • Clostridium chauvoei, strain 1048, cells and equivalent toxoid
    1.00
    90% protective dose in guinea pig
    /
    2.00
    millilitre(s)
  • Clostridium chauvoei, strain 658, cells and equivalent toxoid
    1.00
    90% protective dose in guinea pig
    /
    2.00
    millilitre(s)
  • Clostridium chauvoei, strain 657, cells and equivalent toxoid
    1.00
    90% protective dose in guinea pig
    /
    2.00
    millilitre(s)
  • Clostridium chauvoei, strain 656, cells and equivalent toxoid
    1.00
    90% protective dose in guinea pig
    /
    2.00
    millilitre(s)
  • Clostridium chauvoei, strain 655, cells and equivalent toxoid
    1.00
    90% protective dose in guinea pig
    /
    2.00
    millilitre(s)
  • Tetanus toxoid adsorbed
    2.50
    international unit(s)
    /
    2.00
    millilitre(s)
  • Clostridium septicum, toxoid
    2.50
    international unit(s)
    /
    2.00
    millilitre(s)
  • Clostridium perfringens, type C, strain 578, beta toxoid
    10.00
    international unit(s)
    /
    2.00
    millilitre(s)
  • Clostridium perfringens, type C, strain 554, beta toxoid
    10.00
    international unit(s)
    /
    2.00
    millilitre(s)
  • Clostridium novyi, toxoid
    3.50
    international unit(s)
    /
    2.00
    millilitre(s)
  • Bibersteinia trehalosi, serotype T15, strain S1105/84, Inactivated
    1000000000.00
    cells
    /
    2.00
    millilitre(s)
  • Bibersteinia trehalosi, serotype T10, strain S1075/81, Inactivated
    1000000000.00
    cells
    /
    2.00
    millilitre(s)
  • Bibersteinia trehalosi, serotype T4, strain S1085/81, Inactivated
    1000000000.00
    cells
    /
    2.00
    millilitre(s)
  • Bibersteinia trehalosi, serotype T3, strain S1109/84, Inactivated
    1000000000.00
    cells
    /
    2.00
    millilitre(s)
  • Mannheimia haemolytica, serotype A9, strain S994/77, Inactivated
    1000000000.00
    cells
    /
    2.00
    millilitre(s)
  • Mannheimia haemolytica, serotype A7, strain S1078/81, Inactivated
    1000000000.00
    cells
    /
    2.00
    millilitre(s)
  • Mannheimia haemolytica, serotype A6, strain S1084/81, Inactivated
    1000000000.00
    cells
    /
    2.00
    millilitre(s)
  • Mannheimia haemolytica, serotype A2, strain S1126/92, Inactivated
    1000000000.00
    cells
    /
    2.00
    millilitre(s)
  • Mannheimia haemolytica, serotype A1, strain S1006/77, Inactivated
    1000000000.00
    cells
    /
    2.00
    millilitre(s)
  • Immunoglobulins against Clostridium perfringens epsilon toxoid, Equine
    320.00
    international unit(s)
    /
    2.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Sheep
      • Meat and offal
        0
        day
      • Milk
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI02AB11
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Germany
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Intervet Deutschland GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Intervet International B.V.
Responsible authority:
  • Paul-Ehrlich-Institut
Authorisation number:
  • 73a/97
Date of authorisation status change:

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 27/02/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."